- Home
- TOST vs ROIV Comparison
TOST vs ROIV Comparison
Compare TOST & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOST | ROIV |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 15.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TOST | ROIV |
|---|---|---|
| Price | $27.73 | $25.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 8 |
| Target Price | ★ $44.86 | $24.31 |
| AVG Volume (30 Days) | ★ 10.8M | 5.6M |
| Earning Date | 02-12-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $5,858,000,000.00 | $13,310,000.00 |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $20.61 | $741.42 |
| P/E Ratio | $63.47 | ★ N/A |
| Revenue Growth | ★ 25.76 | N/A |
| 52 Week Low | $26.92 | $8.73 |
| 52 Week High | $49.66 | $23.91 |
Technical Indicators
Market Signals| Indicator | TOST | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 28.65 | 66.92 |
| Support Level | $26.92 | $20.99 |
| Resistance Level | $32.17 | $22.49 |
| Average True Range (ATR) | 1.19 | 0.67 |
| MACD | -0.58 | 0.00 |
| Stochastic Oscillator | 10.98 | 95.62 |
Price Performance
Historical ComparisonAbout TOST Toast Inc.
Toast is an end-to-end technology platform designed to address the complex needs of the restaurant industry. The company generates point-in-time revenue through sales of its restaurant-grade hardware and recurring revenue in the form of take rates on restaurant transaction volume as well as subscriptions to its software solutions. As of fiscal 2024, the company provided services to 134,000 restaurant locations primarily in the US. Toast's typical customer is a mid-market restaurant generating slightly more than $1 million in revenue annually.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.